Publications
405
Citations
2,633
Est. group size
~38
Recurring co-author estimate
Active years
37
Publishing since 1990
This record appears to combine work from multiple researchers publishing under the name Ning Jin, spanning cancer clinical trials (PARP inhibitors, immunotherapy combinations), basic cancer biology, virology/immunology, and unrelated topics like optics and atmospheric science. Because the topic scores are all listed at 0.00 and the publication subjects are highly inconsistent, this profile likely reflects a name-matching issue rather than a single coherent research program. Prospective students should verify affiliation and specific publication list directly with the individual before drawing conclusions about research focus.
Publication counts show a sharp and unusual increase from single digits per year (2017-2022) to 46, 172, and 78 in 2023-2025, a pattern more consistent with aggregation of multiple authors than a single researcher's typical output.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Genes related to neural tube defects and glioblastoma
Scientific Reports · 2025
- PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cancer
OncoImmunology · 2025
- Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers
ESMO Open · 2025
- Thyroglobulin mRNA ectopic expression was an excellent marker to detect lymph node metastasis for patients with papillary thyroid cancer
Clinical and Translational Discovery · 2025
- Mesenchymal stromal cells ameliorate hyperammonemia in acute hepatic failure via inhibiting glutaminolysis
Chinese Medical Journal · 2025
- Dynamic Covalent Hydrogel as a Single-Dose Vaccine Adjuvant for Sustained Antigen Release and Significantly Elevated Humoral Immunity
UNC Libraries · 2025
- An Analysis and Optimization of Distortion Effect Caused by Pupil Decentering in Optical Gun Scope
Photonics · 2024
- Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)
International Journal of Oncology · 2023
- Regulation of the CB1R/AMPK/PGC-1α signaling pathway in mitochondria of mouse hearts and cardiomyocytes with chronic intermittent hypoxia
Sleep And Breathing · 2023
- Spatiotemporal Patterns and Characteristics of PM2.5 Pollution in the Yellow River Golden Triangle Demonstration Area
Atmosphere · 2023
- A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer.
Journal of Clinical Oncology · 2023
- Mesenchymal stromal cells ameliorate hyperammonemia via IGF1-IGF1R- GLS2 axis inhibiting glutaminolysis in acute hepatic failure
Research Square · 2023
- Avelumab Plus Talazoparib in Patients With <i>BRCA1/2</i>- or <i>ATM</i>-Altered Advanced Solid Tumors
JAMA Oncology · 2022
- Simulation of external stray light in airborne off-axis four mirrors telescope system
2022
- Newcastle Disease Virus Inhibits the Proliferation of T Cells Induced by Dendritic Cells In Vitro and In Vivo
Frontiers in Immunology · 2021
- Journal of Clinical Oncology×23
- Cancer Research Communications×5
- Cancers×4
- PubMed×4
- bioRxiv (Cold Spring Harbor Laboratory)×4
- Marium Husain
Medicine · The Ohio State University
- Gabriel Tinoco
Medicine · The Ohio State University
- Rebecca Hoyd
Medicine · The Ohio State University
- Daniel Spakowicz
Medicine · The Ohio State University
- Qin Ma
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile